scholarly journals Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: A prospective, randomized, open-label study

2015 ◽  
Vol 64 (2) ◽  
pp. 161-168 ◽  
Author(s):  
Daisuke Murakami ◽  
Motohiro Sawatsubashi ◽  
Sayaka Kikkawa ◽  
Masayoshi Ejima ◽  
Akira Saito ◽  
...  
Keyword(s):  
Japanese Cedar ◽  
Oral Immunotherapy ◽  
Short Term ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy ◽  
Japanese Cedar Pollinosis

scholarly journals Effect of short-term oral immunotherapy with Cry j 1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study

2016 ◽  
Vol 119 (9) ◽  
pp. 1263-1264
Author(s):  
Daisuke Murakami ◽  
Motohiro Sawatsubashi ◽  
Sayaka Kikkawa ◽  
Masayoshi Ejima ◽  
Akira Saito ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Japanese Cedar ◽  
Oral Immunotherapy ◽  
Short Term ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Japanese Cedar Pollinosis

Effect of short-term oral immunotherapy with Cry j1–galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study

2016 ◽  
Vol 43 (1) ◽  
pp. 50-55 ◽  
Author(s):  
Daisuke Murakami ◽  
Motohiro Sawatsubashi ◽  
Sayaka Kikkawa ◽  
Masayoshi Ejima ◽  
Akira Saito ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Japanese Cedar ◽  
Oral Immunotherapy ◽  
Short Term ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Japanese Cedar Pollinosis

scholarly journals Safety and Efficacy of Oral Human Parathyroid Hormone (1‐34) in Hypoparathyroidism: An Open‐Label Study

2021 ◽  
Author(s):  
Sofia Ish‐Shalom ◽  
Yoseph Caraco ◽  
Nariman Saba Khazen ◽  
Michal Gershinsky ◽  
Auryan Szalat ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy

Fluvoxamine in the Treatment of Trichotillomania: An 8-Week, Open-Label Study

CNS Spectrums ◽  
1998 ◽  
Vol 3 (9) ◽  
pp. 64-71 ◽  
Author(s):  
Gary A. Christenson ◽  
Scott J. Crow ◽  
James E. Mitchell ◽  
Thomas B. Mackenzie ◽  
Ross D. Crosby ◽  
...  
Keyword(s):  
Treatment Response ◽  
Term Treatment ◽  
Hair Pulling ◽  
Short Term ◽  
Open Label ◽  
Short Term Treatment ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

AbstractThis short-term, open-label study investigates short- and long-term effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for the treatment of trichotillomania (TTM). Additionally, this study aimed to test the hypothesis that the presence of hair pulling compulsiveness is predictive of SSRI response. Nineteen subjects meeting the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised, (DSM-III-R) criteria for TTM were treated with fluvoxamine at doses up to 300 mg/day. Random regression analysis of change across time for patients who completed the study (n=14) and those who dropped out (n=5) revealed statistically significant improvements in Physician Rating Scale, hair-pulling episodes, Trichotillomania Impairment Scale, and Trichotillomania Symptom Severity Scale, but not in estimated amount of hair pulled. In addition, the percentage of patients' focused or compulsive hair-pulling symptoms was predictive of treatment response. Unfortunately, all three subjects who entered long-term treatment displayed substantial movement back toward baseline by the end of 6 months. We concluded that fluvoxamine produces moderate reductions in symptoms during the short-term treatment of TTM and that the presence of focused or compulsive hair pulling may be predictive of treatment response. However, responses may be short lived when treatment is extended.

Sign in / Sign up

Export Citation Format

Share Document